Related Experiment Video
Updated: Jan 13, 2026
Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
Published on: June 23, 2020
Latest Achievements in the Development of Nanoparticle-Based Drug Delivery Systems of Pt Drugs and Prodrugs in Cancer
Vlad Iova1, Gilda Mihaela Iova2, Andreea Taisia Tiron1,3
1Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy Bucharest, 020021 Bucharest, Romania.
Abstract:
Even though Pt(II)-based drugs represent the standard in cancer therapy, their use is seriously limited by severe side-effects (renal toxicity, allergic reactions, gastrointestinal disorders, hemorrhage and hearing loss), drug resistance and a grim prognosis. This review presents the results of multiple studies showing different nanoparticle-based platforms as delivery agents in order to overcome these drawbacks. The approach of using nanoparticle-based drug delivery systems of Pt drugs and prodrugs is promising due to key advantages like specific targeting and thereby reduced toxicity to healthy cells; increased stability in the bloodstream; multiple mechanisms of action such as stimulating anti-tumor immunity, responding to environmental stimuli (light, pH, etc.), or penetrating deeper into tissues; enhanced efficacy by their combination with other therapies (chemotherapy, gene therapy) to amplify the anti-tumor effect. However, certain challenges need to be overcome before these solutions can be widely applied in clinics. These include issues related to biocompatibility, large-scale production, and regulatory approvals. In conclusion, using nanoparticles to deliver Pt-based drugs represents an advanced and highly promising strategy to make chemotherapy more effective and less toxic. Nonetheless, further studies are required for the better understanding of intracellular mechanisms of action, toxicity and the pharmacokinetics of nanoparticles, and physical-chemical standardization.
Insights
Nanoparticle drug delivery systems show promise for improving platinum (Pt)-based chemotherapy by reducing side effects and enhancing efficacy. Further research is needed to address challenges for clinical application.
Area of Science:
- Nanomedicine
- Materials Science
- Oncology
Background:
- Platinum (Pt)-based drugs are standard cancer treatments but have significant limitations.
- Severe side effects, drug resistance, and poor prognosis hinder Pt-drug efficacy.
- Nanoparticle-based delivery offers a promising strategy to overcome these challenges.
Purpose of the Study:
- To review the potential of nanoparticle-based platforms for delivering Pt drugs and prodrugs.
- To highlight the advantages of nanodelivery systems in cancer therapy.
- To identify challenges hindering clinical translation of these advanced systems.
Main Methods:
- Comprehensive literature review of studies on nanoparticle-based drug delivery for Pt drugs.
- Analysis of advantages including targeted delivery, reduced toxicity, and enhanced efficacy.
- Identification of challenges such as biocompatibility, production, and regulatory hurdles.
Main Results:
- Nanoparticle systems offer targeted delivery, reducing toxicity to healthy cells.
- These systems enhance drug stability, enable multiple action mechanisms, and improve tissue penetration.
- Combination therapies with nanodelivery amplify anti-tumor effects.
Conclusions:
- Nanoparticle-mediated delivery of Pt-based drugs is a highly promising strategy for effective and less toxic cancer chemotherapy.
- Further investigation into intracellular mechanisms, toxicity, pharmacokinetics, and standardization is crucial.
- Overcoming challenges in biocompatibility, production, and regulation is essential for clinical application.
